What is the clinical evidence from this study?

Study design: RCT. Population: Coronary artery disease (n=38). Intervention: Coenzyme Q10 vs. Placebo. Primary outcome: Extracellular superoxide dismutase (ecSOD) activity and endothelium-dependent (ED) vasodilation.

What question did this study set out to answer?

To assess the effects of oral coenzyme Q10 on endothelial function and superoxide dismutase activity in patients with coronary artery disease.

June 12, 2026European Heart JournalOpen Access

Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study

Q: What are the key findings of this study?

Oral coenzyme Q10 (300 mg/day) significantly improved endothelium-dependent relaxation and extracellular superoxide dismutase activity compared to placebo in patients with coronary artery disease.

Q: What does this research mean for the field?

Oral coenzyme Q10 supplementation improves endothelium-dependent relaxation, extracellular superoxide dismutase activity, and exercise capacity in patients with coronary artery disease. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Coenzyme Q10 improves endothelial function and extracellular superoxide dismutase activity vs placebo in CAD.

n=38

Why the study?

Does oral coenzyme Q10 improve extracellular superoxide dismutase activity and endothelium-dependent vasodilation in patients with coronary artery disease?

Key Points

To assess the effects of oral coenzyme Q10 on endothelial function and superoxide dismutase activity in patients with coronary artery disease.
Randomized controlled trial involving 38 CAD patients, 100 mg CoQ(10) administered thrice daily for one month.
Brachial artery assessment, cardiopulmonary exercise tests, and ecSOD activity measurements at baseline and one month post-intervention.
Comparative analysis between CoQ(10) and placebo groups.
CoQ(10) supplementation resulted in statistically significant improvements in endothelial function and ecSOD activity, with a mean increase of ecSOD in the treatment group.
Enhanced peak VO(2) observed in the CoQ(10) group, indicating greater exercise capacity (p<0.05).
Significant effects were noted particularly in participants with low initial ecSOD levels, suggesting a targeted therapeutic role of CoQ(10) in oxidative stress.

Study Design

Type

RCT (n=38)

Blinding

Double-blind

Randomization

randomized

Structured PICO

Does oral coenzyme Q10 improve extracellular superoxide dismutase activity and endothelium-dependent vasodilation in patients with coronary artery disease?

Population

38 patients with coronary artery disease (mean age 55 years, 13% female) randomized to receive oral coenzyme Q10 or placebo for 1 month.

Intervention

Oral coenzyme Q10 100 mg tid (300 mg/day) for 1 month

Comparator

Placebo for 1 month

Outcome

Extracellular superoxide dismutase (ecSOD) activity and endothelium-dependent (ED) vasodilation at 1 monthsurrogate

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Oral coenzyme Q10 supplementation improves endothelial function, extracellular superoxide dismutase activity, and exercise capacity in patients with coronary artery disease.

Cite This Study

Tiano et al. (2007) conducted an RCT in Coronary artery disease (n=38). Coenzyme Q10 vs. Placebo was evaluated on Extracellular superoxide dismutase (ecSOD) activity and endothelium-dependent (ED) vasodilation. Oral coenzyme Q10 (300 mg/day) significantly improved endothelium-dependent relaxation and extracellular superoxide dismutase activity compared to placebo in patients with coronary artery disease.

synapsesocial.com/papers/6a2c2373cbfd45c7f9525afb https://doi.org/10.1093/eurheartj/ehm267

View Full Paper

Ask AI

Bookmark

Implication

Oral coenzyme Q10 supplementation improves endothelial function, extracellular superoxide dismutase activity, and exercise capacity in patients with coronary artery disease.